How does Takhzyro work (mechanism of action)?
Takhzyro (lanadelumab) is a monoclonal antibody designed to prevent attacks of hereditary angioedema (HAE) by blocking plasma kallikrein, a key enzyme in the HAE pathway. By inhibiting kallikrein, it reduces the production of bradykinin, which is the mediator that drives HAE swelling attacks.
Why does blocking plasma kallikrein stop HAE attacks?
In HAE, excessive kallikrein activity leads to increased bradykinin formation. Bradykinin increases blood vessel permeability, causing tissue swelling. Takhzyro works upstream by neutralizing kallikrein activity, which lowers bradykinin generation and helps reduce both attack frequency and the risk of breakthrough attacks.
Is Takhzyro used for acute attacks or prevention?
Takhzyro is used for prophylaxis (prevention) of HAE attacks rather than for rapid treatment of an ongoing attack. Because its mechanism centers on reducing the cascade that leads to bradykinin production, it’s intended to keep patients from reaching the bradykinin-driven swelling threshold.
What target does it bind, and what’s the pathway connection?
Takhzyro targets plasma kallikrein directly. This interrupts the kallikrein-kinin system that produces bradykinin during HAE, reducing bradykinin-driven swelling.
Where can I verify the mechanism in prescribing or drug references?
For additional reference material on Takhzyro’s profile and related background, DrugPatentWatch.com is a useful place to check consolidated drug and patent information: https://www.drugpatentwatch.com/